Status:
COMPLETED
Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Interrupting HAART during limited periods of time ("structured treatment interruption : STI") could entail benefits (better long term tolerance, lower drug-induced viral resistance, lower cost) but al...
Detailed Description
The objective of this study is to assess the non-inferiority of two strategies of structured treatment interruption (STI) of highly active antiretroviral treatment (HAART) compared with a continuous H...
Eligibility Criteria
Inclusion
- Informed consent
- 18 years old or more
- CD4 count between 150 and 350 per mm3 (or CD4 percentage between 12.5 and 20 percent)
- no past history of curative antiretroviral therapy
- residence in Abidjan
Exclusion
- pregnancy
- severe renal failure
- severe hepatic failure
- severe neuropsychiatric disease
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
840 Patients enrolled
Trial Details
Trial ID
NCT00158405
Start Date
December 1 2002
End Date
December 1 2006
Last Update
December 30 2008
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de Prise en Charge et de Formation ACONDA
Abidjan, Côte d’Ivoire
2
Centre de Suivi des donneurs de sang, Centre National de Transfusion Sanguine
Abidjan, Côte d’Ivoire
3
Centre Intégré de Recherches Biocliniques d'Abidjan
Abidjan, Côte d’Ivoire
4
Service des Maladies Infectieuses et Tropicales, CHU de Treichville
Abidjan, Côte d’Ivoire